Early in the HIV epidemic, lipodystrophy, characterized by subcutaneous fat loss
(lipoatrophy), with or without central fat accumulation (lipohypertrophy), was recognized as a …

Body weight is influenced by an interplay of individual and environmental factors. In people
with human immunodeficiency virus (HIV), weight is also influenced by disease status with …

Importance Recent advances in treatment and prevention of HIV warrant updated
recommendations to guide optimal practice. Objective Based on a critical evaluation of new …

Introduction Although weight gain has been reported with the use of integrase strand
transfer inhibitors (InSTI), concurrent use of tenofovir alafenamide (TAF) has been implicated …

Background We sought to identify factors associated with weight gain in randomized clinical
trials of antiretroviral therapy (ART) switch. Methods We explored the effects of demographic …

Background De novo steatosis is the main criteria for non-alcoholic fatty liver disease
(NAFLD), which is becoming a clinically relevant comorbidity in HIV-infected patients. This …

Abstract Background To inform World Health Organization (WHO) global guidelines, we
updated and expanded the evidence base to assess the comparative efficacy, tolerability …

Background Integrase strand transfer inhibitor (INSTI)–based combination antiretroviral
therapy (cART) is associated with greater weight gain among persons with human …

Numerous studies have detected a greater likelihood of excess weight gain with specific
antiretrovirals (ARVs), particularly tenofovir alafenamide and integrase inhibitors, as …

Objective To compare the incidence of hypertension in people living with HIV receiving
integrase strand transfer inhibitor (INSTI)‐based antiretroviral therapy (ART) versus non …